title: Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
abstract: BACKGROUND
  MicroRNAs (miRs) have been implicated in the etiology of various human cancers. The aim of this study was to investigate the association of the expression of three members--miR 200a, miR 200b, and miR 200c belonging to the miR-200 family with clinicopathological characteristics and their impact on the progression of epithelial ovarian cancer (EOC).
  
  
  METHODS
  Total RNA from serum was isolated by Trizol method, polyadenylated, and reverse transcribed into cDNA. Expression levels of miR-200a, miR-200b, and miR-200c were detected by using miRNA qRT-PCR. We measured miR expression in 70 serum samples of EOC patients with matched controls using U6 snRNA as a reference. Levels of miR expression was compared with distinct clinicopathological features.
  
  
  RESULTS
  Expression of miR-200a was found to be greater than six-fold (p = 0.01), miR-200b and miR-200c greater than three-fold (p = 0.01) in comparison with matched normal controls. Association of miRNA expression with clinicopathological factors and progression was statistically evaluated. The expression levels of miR-200a and miR-200c were found to be significantly associated with disease progression (p = 0.04 and p < 0.001, respectively). miR-200a overexpression was found be associated with tumor histology and stage. Patients with lymph node metastasis showed significant elevation of miR-200c (p = 0.006). The AUC in ROC curve also indicated that serum levels of miR-200a and miR-200c might be worthwhile as a diagnostic tool in the near future.
  
  
  CONCLUSIONS
  Our findings suggest that miR-200a, miR-200b, and miR-200c overexpressions are associated with the aggressive tumor progression and be recognized as reliable markers to predict the prognosis and survival in EOC patients.
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
authors.forename: M
authors.initials: M
authors.lastname: Zuberi
authors.affiliation: Prince Fahd Bin Sultan Research Chair, University of Tabuk, Tabuk, 71491, Saudi Arabia.
authors.forename: R
authors.initials: R
authors.lastname: Mir
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
authors.forename: J
authors.initials: J
authors.lastname: Das
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
authors.forename: I
authors.initials: I
authors.lastname: Ahmad
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
authors.forename: J
authors.initials: J
authors.lastname: Javid
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
authors.forename: P
authors.initials: P
authors.lastname: Yadav
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
authors.forename: M
authors.initials: M
authors.lastname: Masroor
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
authors.forename: S
authors.initials: S
authors.lastname: Ahmad
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India.
authors.forename: P C
authors.initials: PC
authors.lastname: Ray
authors.affiliation: Department of Biochemistry, Maulana Azad Medical College, New Delhi, 110002, India. alpanasaxena@hotmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Saxena
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000097:blood / Q000235:genetics / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000235:genetics / Q000473:pathology; D000231:Adenocarcinoma, Papillary / Q000097:blood / Q000235:genetics / Q000473:pathology; D000328:Adult; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D018269:Carcinoma, Endometrioid / Q000097:blood / Q000235:genetics / Q000473:pathology; D000077216:Carcinoma, Ovarian Epithelial; D016022:Case-Control Studies; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D035683:MicroRNAs / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000097:blood / Q000235:genetics / Q000473:pathology; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood / Q000235:genetics* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000097:blood / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D012372:ROC Curve; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D047368:Tumor Burden; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; C533896:MIRN200 microRNA, human; D035683:MicroRNAs
keywords: Biomarker; Disease progression; Overexpression; qRT-PCR